checkAd
    Startseite > Aktien > Veracyte > Nachrichten
    Veracyte Aktie
    21,600
     
    EUR
    -0,46 %
    -0,100 EUR
    Letzter Kurs 22:54:18 Lang & Schwarz
    21,400
     
    EUR
    393 STK
    Geldkurs 22:54:18
    21,800
     
    EUR
    393 STK
    Briefkurs 22:54:18
    ISIN: US92337F1075 · WKN: A1W7EA · USA

    Neueste Nachrichten

    Veracyte to Participate in Upcoming Investor Conferences
    15.05.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces First Quarter 2024 Financial Results
    07.05.24 · Business Wire (engl.) · Veracyte
    14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
    06.05.24 · Business Wire (engl.) · Veracyte
    Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
    22.04.24 · Business Wire (engl.) · Veracyte
    New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
    22.04.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
    16.04.24 · Business Wire (engl.) · Veracyte
    Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
    27.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
    22.02.24 · Business Wire (engl.) · Veracyte
    Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
    21.02.24 · Business Wire (engl.) · Veracyte
    Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
    08.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Completes Acquisition of C2i Genomics
    06.02.24 · Business Wire (engl.) · Veracyte
    Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
    08.01.24 · Business Wire (engl.) · Veracyte